Spanish plasma-derived medicines specialist Grifols revealed it is collaborating with Dutch biotechnology start-up, FcR ...

Grifols, a global healthcare company and leading manufacturer of plasma-derived medicines, has announced a collaboration with biotechnology startup FcR Therapeutics to develop recombinant nanobodies ...

As global markets navigate a volatile start to 2025, with the Federal Reserve holding rates steady and AI competition shaking up the tech sector, investors are closely watching how these dynamics ...

Rising Incidence of Hemophilia, Immunological Disorders, and the Growing Number of Surgical Procedures Worldwide is Driving Growth, at a CAGR of ~9%Dublin, Feb. 06, 2025 (GLOBE NEWSWIRE) -- The "Blood ...

Q3 2025 Earnings Call Transcript February 6, 2025 Operator: Good day, and welcome to the Haemonetics Third Quarter Fiscal ...

UEFA has today announced that Unilever, a global leader in consumer goods, has become an official global partner of UEFA ...

Haemonetics updated its hospital revenue guidance to 24% to 26% reported growth and 12% to 14% organic growth, driven by strong adoption of hemostasis cartridges and vascular closure devices.

European equities traded in the US as American depositary receipts were tracking lower late Friday morning, declining 0.25% to 1,383.65 on the S&P Europe Select ADR Index. Despite the loss the index ...

The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almost $6 ...

Grifols has filed for US approval of a new drug for rare bleeding disorder acquired fibrinogen deficiency (AFD), which promises to provide a more reliable and easier treatment for patients.